Ascentage Pharma Group International (AAPG) Cash & Equivalents: 2022-2024
- Ascentage Pharma Group International's Cash & Equivalents fell 15.13% to $122.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $122.4 million, marking a year-over-year decrease of 15.13%. This contributed to the annual value of $122.4 million for FY2024, which is 13.96% down from last year.
- Per Ascentage Pharma Group International's latest filing, its Cash & Equivalents stood at $122.4 million for Q4 2024, which was down 15.13% from $144.2 million recorded in Q4 2023.
- In the past 5 years, Ascentage Pharma Group International's Cash & Equivalents registered a high of $189.2 million during Q4 2022, and its lowest value of $122.4 million during Q4 2024.
- For the 3-year period, Ascentage Pharma Group International's Cash & Equivalents averaged around $151.9 million, with its median value being $144.2 million (2023).
- Data for Ascentage Pharma Group International's Cash & Equivalents shows a maximum YoY dropped of 23.80% (in 2023) over the last 5 years.
- Over the past 3 years, Ascentage Pharma Group International's Cash & Equivalents (Quarterly) stood at $189.2 million in 2022, then dropped by 23.80% to $144.2 million in 2023, then dropped by 15.13% to $122.4 million in 2024.
- Its Cash & Equivalents was $122.4 million in Q4 2024, compared to $144.2 million in Q4 2023 and $189.2 million in Q4 2022.
